STENOCARE has started trading. You can follow the share HERE.
Gemstone advised STENOCARE in its IPO process and is proud to report that the subscription turned out in excess of everybody’s expectation. You may read more about the subscription outcome HERE.
Below, this page will give you’re an overview of and access to relevant news, information and insights. The medical cannabis market is in its infancy, especially in Europe and STENOCARE is the first IPO within medical cannabis in Europe.
Subscription period has ended.
STENOCARE A/S new share issue significantly oversubscribed
Gemstone Capital is advising STENOCARE in its IPO on Spotlight Stock Market. Gemstone Capital has options in STENOCARE, but is not a shareholder. Gemstone is not responsible for any third party content. All content on this page is provided for informational purposes only. It does not constitute or form part of, and shall under no circumstances be considered as, an offer to sell or a recommendation or solicitation of an offer to purchase or sell any relevant financial instruments. For information about STENOCARE and the risks involved in any investment, please read the Memorandum provided carefully.